Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced critical concentration might not have improved MGIT-based DST's sensitivity to rifampicin.
Rupasinghe P, Ashraf A, Barreda N, Parveen S, Zubair M, Calderon R, Asif S, Hirani N, Chingisova L, Bulane A, Hang PT, Ha DT, Ardizzoni E, Kursheed N, De Rijk WB, Rigouts L, Guglielmetti L, Mitnick C, de Jong BC. Rupasinghe P, et al. Among authors: de jong bc. Antimicrob Agents Chemother. 2024 May 2;68(5):e0170123. doi: 10.1128/aac.01701-23. Epub 2024 Mar 27. Antimicrob Agents Chemother. 2024. PMID: 38534101 No abstract available.
Rifampicin resistance conferring mutations among Mycobacterium tuberculosis strains in Rwanda.
Cuella-Martin I, Semuto Ngabonziza JC, Torrea G, Meehan CJ, Mulders W, Ushizimpumu B, De Weerdt L, Keysers J, De Rijk WB, Decroo T, De Jong BC, Rigouts L. Cuella-Martin I, et al. Among authors: de jong bc. Int J Mycobacteriol. 2023 Jul-Sep;12(3):274-281. doi: 10.4103/ijmy.ijmy_103_23. Int J Mycobacteriol. 2023. PMID: 37721232 Free article.
Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown.
Van Deun A, Decroo T, Aung KJM, Hossain MA, Gumusboga M, De Rijk WB, Tahseen S, de Jong BC, Rigouts L. Van Deun A, et al. Among authors: de jong bc, de rijk wb. Eur Respir J. 2021 Sep 2;58(3):2100783. doi: 10.1183/13993003.00783-2021. Print 2021 Sep. Eur Respir J. 2021. PMID: 33926970 Free article. No abstract available.
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, Austin A, Baudin E, Bekhit M, Bektasov S, Berikova E, Bonnet M, Caboclo R, Chaudhry M, Chavan V, Cloez S, Coit J, Coutisson S, Dakenova Z, De Jong BC, Delifer C, Demaisons S, Do JM, Dos Santos Tozzi D, Ducher V, Ferlazzo G, Gouillou M, Khan U, Kunda M, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moreau M, Moschioni M, Nahid P, Osso E, Oyewusi L, Panda S, Pâquet A, Thuong Huu P, Pichon L, Rich ML, Rupasinghe P, Salahuddin N, Sanchez Garavito E, Seung KJ, Velásquez GE, Vallet M, Varaine F, Yuya-Septoh FJ, Mitnick CD, Guglielmetti L. Patil SB, et al. Among authors: de jong bc. Trials. 2023 Nov 30;24(1):773. doi: 10.1186/s13063-023-07701-6. Trials. 2023. PMID: 38037119 Free PMC article.
Refined understanding of the impact of the Mycobacterium tuberculosis complex diversity on the intrinsic susceptibility to pretomanid.
Rupasinghe P, Reenaers R, Vereecken J, Mulders W, Cogneau S, Merker M, Niemann S, Vally Omar S, Rigouts L, Köser CU, Decroo T, de Jong BC. Rupasinghe P, et al. Among authors: de jong bc. Microbiol Spectr. 2024 Mar 5;12(3):e0007024. doi: 10.1128/spectrum.00070-24. Epub 2024 Feb 9. Microbiol Spectr. 2024. PMID: 38334384 Free PMC article.
205 results